Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Motzer

Showing results (1-10 of 436) with videos related to

Pageof 44
Sort By:
Critical Reviews in Oncology/Hematology|July 10, 2003
Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinomaRobert J Motzer
The Oncologist|February 25, 2011
New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overviewRobert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Renal cell carcinoma: a priority malignancy for development and study of novel therapiesRobert J Motzer
Nature|September 15, 2016
Perspective: What next for treatment?Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2003
Poor-risk testicular cancer and high-dose chemotherapyRobert J Motzer, Sheinfeld Sheinfeld
Lancet (London, England)|December 25, 2007
Targeted drugs for metastatic renal cell carcinomaRobert J Motzer, Ethan Basch
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
Ten years of progress in renal cell carcinomaEric Jonasch, Robert J Motzer
The New England Journal of Medicine|June 5, 2018
Cytoreductive Nephrectomy - Patient Selection Is KeyRobert J Motzer, Paul Russo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Stage I testicular cancer management and necessity for surgical expertiseJoel Sheinfeld, Robert J Motzer
The New England Journal of Medicine|June 27, 2019
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. ReplyRobert J Motzer, Bo Huang
Pageof 44

Showing results (1-10 of 436) with videos related to

Sort By:
Pageof 44
Critical Reviews in Oncology/Hematology|July 10, 2003
Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinomaRobert J Motzer
The Oncologist|February 25, 2011
New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overviewRobert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Renal cell carcinoma: a priority malignancy for development and study of novel therapiesRobert J Motzer
Nature|September 15, 2016
Perspective: What next for treatment?Robert J Motzer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2003
Poor-risk testicular cancer and high-dose chemotherapyRobert J Motzer, Sheinfeld Sheinfeld
Lancet (London, England)|December 25, 2007
Targeted drugs for metastatic renal cell carcinomaRobert J Motzer, Ethan Basch
Journal of the National Comprehensive Cancer Network : JNCCN|June 9, 2012
Ten years of progress in renal cell carcinomaEric Jonasch, Robert J Motzer
The New England Journal of Medicine|June 5, 2018
Cytoreductive Nephrectomy - Patient Selection Is KeyRobert J Motzer, Paul Russo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Stage I testicular cancer management and necessity for surgical expertiseJoel Sheinfeld, Robert J Motzer
The New England Journal of Medicine|June 27, 2019
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. ReplyRobert J Motzer, Bo Huang
Pageof 44